Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

August 26, 2021

Study Completion Date

October 27, 2021

Conditions

Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

OTHER

Best Practice

Receive standard of care drugs

DRUG

Leflunomide

Given PO

DRUG

Placebo Administration

Given PO

Trial Locations (1)

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT04532372 - Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy | Biotech Hunter | Biotech Hunter